Post-Market NASDAQ Movers (MOTR, CTAS, XING, EEFT, WRLD, XOMA, DBLE, SUNS, ACOM, UTHR)

The top after-market NASDAQ stock market gainers are: Motricity, Cintas, Qiao Xing Universal Resources, Euronet Worldwide, and World Acceptance. The top after-market NASDAQ stock market losers are: XOMA, Double Eagle Petroleum, Solar Senior Capital, Ancestry.com, and United Therapeutics.

Gainers

Motricity, Inc. (MOTR) stock soared 6.18 percent to $15.29 in the after-market trading.

Cintas Corp. (CTAS) stock grew 6.04 percent to $29.84 in the after-market trading, as its third quarter earnings and revenue exceeded Street view. Profit was $59.1 million or 41 cents a share, up from $49.0 million or 32 cents a share last year. Revenue rose 8.8 percent to $937.83 million. Analysts had expected profit of 36 cents a share on revenue of $907.56 million.

Cintas tightened its full year 2011 earnings guidance to range of $1.60 to $1.63 a share from previous forecast of $1.55 to $1.63 a share. The company raised its revenue outlook to range of $3.75 billion to $3.77 billion from previous range of $3.55 billion to $3.75 billion. Analysts predict profit of $1.58 a share on revenue of $3.73 billion.

Qiao Xing Universal Resources, Inc. (XING) stock gained 3.38 percent to $2.14 in the after-market trading.

Euronet Worldwide Inc. (EEFT) stock increased 3.10 percent to $18.805 in the after-market trading.

World Acceptance Corp. (WRLD) stock rose 2.97 percent to $63.76 in the after-market trading.

Losers

XOMA Ltd. (XOMA) stock plunged 38.25 percent to $3.10 in the after-market trading, as its lead type-2 diabetes drug failed to lower glucose levels in patients in a mid-stage study. The company said its phase 2b trial of XOMA 052 in type 2 diabetes patients did not achieve the primary endpoint of reduction in glycosylated hemoglobin, or HbA1c, after six monthly treatments with XOMA 052 compared to placebo. XOMA is developing XOMA 052 in collaboration with Servier.

Biological activity of XOMA 052 supporting its potential in cardiovascular disease was observed with highly significant decreases in C-reactive protein, or CRP, a biomarker for the risk of heart attack, stroke and other cardiovascular diseases, in all dose groups versus placebo. In addition, statistically significant improvements in high-density lipoprotein, or good cholesterol were observed in two of four XOMA 052 dose groups versus placebo.

Double Eagle Petroleum Co. (DBLE) stock fell 4.92 percent to $7.93 in the after-market trading.

Solar Senior Capital Ltd. (SUNS) stock slid 2.85 percent to $18.75 in the after-market trading.

Ancestry.com Inc. (ACOM) stock declined 2.46 percent to $30.90 in the after-market trading.

United Therapeutics Corp. (UTHR) stock decreased 1.77 percent to $63.95 in the after-market trading.